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Summary 
We have analyzed the V/~ usage by CD4 + and CD8 + T cells from human immunodeficiency 
virus (HIV)-infected individuals in response to an in vitro stimulation with the superantigenic 
erythrogenic toxin A (ETA) of Streptococcus ivogenes.  ETA amplifies specifically  CD4 + and CD8 + 
T  ceils from control donors expressing the V~8 and the VB12 dements. When peripheral T 
ceils from asymptomatic HIV-infected individuals were stimulated with ETA, there was a complete 
lack of activation  of the V/~8  + T  cell subset,  whereas  the V~12 + T  cell subset  responded 
normally to the superantigen.  This V~-specific anergy, which was also observed in response 
to staphylococcal enterotoxin E (SEE), affected both CD4 + and CD8 + T cells and represented 
an intrinsic  functional defect rather than a specific lack of response to bacterial superantigens 
since it was also observed after a stimulation with V//8 monoclonal antibodies. The V/~8 anergic 
T ceils did not express interlenkin 2 receptors (IL-2Rs) and failed to proliferate in response to 
exogenous IL-2 or IL-4,  suggesting that this anergy was not a reversible process, at least by 
the use of these cytokines. The unresponsiveness of the V~8 T cell subset is frequent since it 
was found in 56%  of the patients  studied,  and comparison  of the clinical status of responder 
vs. anergic patients indicated that the only known common factor between them was HIV infection. 
In addition, it is noteworthy that the anergy of the V~8 subset may be a very early phenomenon 
since it was found in a patient at Centers for Disease Control stage I of the disease. These data 
provide evidence that a dominant superantigen may be involved in the course of HIV infection 
and that the contribution of HIV has to be considered. 
S 
ome infectious  agents such as pathogenic bacteria  and 
retroviruses seem to have evolved  towards a similar strategy 
to influence the immune system of the host and to facilitate 
infection, by expressing molecules that have features of su- 
perantigens.  Exogenous bacterial superantigens  comprise a 
set of protein toxins produced by Staphylococcus, Streptococcus, 
or Mycoplasraa that are recognized, in the context of MHC 
class II molecules, by T cells expressing particular TCR V~ 
gene families, causing strong T cell activation associated with 
toxic shock and autoimmune diseases (1-5).  The immuno- 
logical properties of bacterial superantigens are reminiscent 
of the Mls antigens that were shown to be encoded by the 
3' open reading frame of mouse mammary tumor virus and 
were responsible for the activation and subsequent deletion 
of CD4 + T ceil subsets expressing V~ dements that react 
with this retroviral superantigen (6-10). Involvement of su- 
perantigens in the pathogenesis of murine infections was also 
Part of this work has been presented  in a preliminary  report as a letter 
to the editor (1993. Lancet. 50-51). 
reported with a variant of MuLV encoding for a truncated 
gag fusion protein which possessed superantigenic proper- 
ties and was shown to be responsible for the routine acquired 
immunodeficiency syndrome (11-13). 
Since HIV-1 is a retrovirus,  and since the pathology of 
HIV infection and AIDS involves predominantly the same 
CD4 + T cells that are commonly involved in superantigen- 
associated phenomenons, it was suggested that HIV might 
cause, in conjunction with dass II genes, cell anergy and deple- 
tion of noninfected CD4 + T cells bearing TCR Vfl deter- 
minants, by encoding a superantigen expressed by activated 
infected cells (14). Recent studies (15-17) reported significant 
perturbations of the TCR Vfl repertoire in HIV-infected sub- 
jects, suggesting the contribution of superantigens in AIDS 
pathogenesis. 
In vivo studies of peripheral tolerance using either Mls an- 
tigens or bacterial enterotoxins have shown that after expan- 
sion of T cells bearing the cognate Vfl determinants,  the re- 
maining T  cells are unresponsive  to restimulation by the 
super'antigen in vitro (T cell anergy) (18-21). Therefore, anergy 
of a given Vfl T cell subset gives evidence of a previous acti- 
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Volume  179  February  1994  413-424 vation  of this  subset by a  superantigen.  We have used  the 
streptococcal erythrogenic  toxin A  (ETA) 1 (22)  to analyze 
the VB usage of peripheral T  cells from asymptomatic HIV- 
infected subjects in response to this superantigenic activation. 
Our data indicate the existence, in a large fraction of infected 
individuals,  of a  V~-specific anergy affecting both  CD4 + 
and CD8 + T  cells that express the VB8 TCR element.  We 
have characterized  this  V~/-specific anergy and have shown 
that it was not restricted to an ETA stimulation but repre- 
sented  an intrinsic  functional  defect.  The precocity of this 
phenomenon  and the  absence of correlation with  previous 
viral or bacterial opportunistic infections suggest the involve- 
ment  of an  HIV-associated  superantigen. 
Materials  and Methods 
Blood Samples.  Peripheral blood was obtained from 43  HIV- 
infected individuaLs in the Service des Maladies infectieuses (Professor 
R. R_ou6, HSpital Militaire B6gin,  Saint Mand6, France).  Of 38 
men  and  5  women,  30  were clinically  asymptomatic (stage  II 
classification  of the Centers for Disease Control [CDC], Atlanta, 
GA), 13 were CDC stage IIA (CD4 •500/mm3),  17 were CDC 
stage liB (CD4 <500/ram3),  1 patient was CDC stage I (3 wk 
after primo infection), 2 patients were CDC stage III, and 9 pa- 
tients CDC were stage IV. Controls (n =  15) were HIV-seronegative 
healthy donors and one HIV-seronegadve donor with infectious 
mononucleosis. 
MonoclonalAntibodies.  The mAbs used in this study were CD4 
(IgG1, g), CD8 (IgG1, g), CD3 (IgG1, g), and CD25 (IgG1, g), 
purchased from Becton Dickinson (Pont de Claix, France). mAbs 
specific for human TCR V region epitopes (Diversi-T  c~O TCR) 
were purchased  from T  Cell Sciences  (Bioadvance,  Le Perreux, 
France):  mAbs 1C1 and Wl12 recognize either both VB5.2 and 
VB5.3 or only the V~5.3 subfamily; mAb LC4 is specific to the 
V~5.1  subfamily; mAbs 16G8 and $511 mAb are specific to the 
VO8 and V~12 subfamilies,  respectively; and ceV2a mAb (done 
F1) is specific to the V~2  subfamily. 
Cell Preparation and Stimulation.  PBMC  were  isolated  from 
heparinized blood by centrifugation on Ficoll-Hypaque (Pharmacia, 
Sweden) and cultured at 106 cells/ml of complete medium com- 
posed  of  RPMI-1640  supplemented  with  10%  vol/vol  heat- 
inactivated  FCS,  2  mM  L-glutamine,  20  mM Hepes,  10  U/ml 
penicillin-streptomycin.  Cultures were stimulated with optimal con- 
centrations of bacterial superantigens: 1 ~g/ml ETA of Streptococcus 
t,yogenes (a gift from Dr. H. MCdler-Alouf, Institut Pasteur) or 1 
~g/ml staphylococcal enterotoxin E (SEE) (Sigma Chemical Co., 
St. Louis, MO). Stimulation lasted 4 d for ETA or 11 d for SEE, 
1 Abbreviations used in  this paper: ETA, erythrogenic  toxin  A;  SEB, 
staphylococcal enterotoxin  B;  SEE, staphylococcal enterotoxin  E;  SI, 
stimulation index. 
and in this latter case, 20 U/ml riD2 (Boehringer Mannheim, Mann- 
helm, Germany) was added at day 3. 
T Cell Proliferation Assays.  Proliferation assays were performed 
in 96-well culture plates (Costar, Brumath, France) in a final volume 
of 200 ~1. Polydonal T cell proliferation was induced by 600 ng/ml 
anti-CD3 mAbs (Dakopatts, Trappes, France).  Specific anti-Vfl-in- 
duced proliferation was performed in microwells coated with purified 
mAbs specific for human TCR V region epitopes (Diversi-T  c~/~ 
TCR, T  Cell Sciences).  Coating of microwells was performed as 
follows, mAbs were diluted at 10 #g/ml in PSS and incubated over- 
night at 4~  (30 #l/microtiter flat-bottom well). Plates were then 
washed three times with PBS before adding 4  x  10  s PBMC/well. 
rlL-2 was added at 20 U/ml after 3 d, and cultures were pulsed 
3 d later with  1/~Ci of [3H]thymidine (5 Ci/mmol) during the 
final 16 h of incubation. Each culture was done in triplicate wells. 
Results are indicated as stimulating index (SI) which corresponds 
to mean cpm obtained in cultures coated with anti-VB mAbs divided 
by mean cpm obtained in medium alone. 
Immunofluorescent Analysis.  Comparison of the expression of 
TCR V  gene products by CD3 +, CD4 +, or CD8 § T  cells iso- 
lated from HIV-infected patients or controls was done as follows: 
5  x  10  s PBMC were washed three times in PBS containing 1% 
BSA and 0.1% sodium azide and incubated for 10 rain at 4~  with 
anti-CD3, -CD4, or -CD8 mAbs (Becton Dickinson) conjugated 
with PE and with a panel of mAbs specific for human TCR V 
region epitopes (T Cell Sciences), conjugated with FITC. Isotypi- 
cally matched negative controls were used (FITC or PE-conjugated 
mouse mAbs from Becton Dickinson). All samples were fixed with 
1% paraformaldehyde and immediately acquired in a FACScan | 
flow cytometer (Becton Dickinson). For each sample, 20,000 double- 
stained viable lymphocytes were gated following size (FSC)  and 
granulosity (SSC)  criteria and analyzed with the Lysis program 
(Becton Dickinson). The number of positive cells for both CD3 
(CD4 or CD8) and the TCR V region for each sample was com- 
pared with  the corresponding control samples. 
Analysis of the V~ usage by CD4 + or CD8 + T cells from HIV- 
infected or control individuals in response to a superantigenic acti- 
vation was performed with the same staining procedure as described 
above.  FACS  |  analysis  of double-stained activated cells was per- 
formed simultaneously  on two gated populations,  e.g., the K1 popu- 
lation corresponding to small cells and the R2 population corre- 
sponding to blastic cells (see Fig. 1). To accurately compare, between 
different donors, T  cell subpopulations bearing a given V~ after 
in vitro activation, results were calculated as the percentage of T 
cell blasts bearing a particular V~ after stimulation divided by the 
percentage of T cells bearing that Vfl before stimulation. Analysis 
of IL-2K (CD25) expression on V~ + T  cell subpopuhtious con- 
secutively to ETA stimulation was performed as described above, 
but was restricted to the K1 population (small cells) to allow com- 
parison between  the group of anergic HIV-infected donors  and 
groups of responder HIV-infected donors and controls. The Mann- 
Whitney U test was used to compare the different groups of indi- 
viduals. 
Figure  1.  V~ usage ofCD4 + and CD8 + human T cells in response to ETA. PBMC from normal donors were analyzed before (A) and after (B) 
4-d ETA stimulation (1 t~g/ml) and two gates were defined following size (FSC) and granulosity (SSC) criteria. Gate R1 corresponded to small cells 
(A) and gate R2 to bhst cells (B). Analysis of the VB usage by CD4 + T cells in response to ETA was realized by dual staining with CD4-PE mAb 
and anti-V~-FITC mAbs before (C-E)  and after (F-K) stimulation. Numbers in quadrants indicate the percentage of CD4+VB § or CD4-Vfl + T 
cells subsets in gate R1 or gate R2. To visualize V~-specific stimulation by ETA, results are expressed as index calculated as the percentage of CD4+ 
T cell blasts bearing a particular VB after stimulation divided by the percentage of CD4 + T cells beating that VB before stimulation ~_). Thus an 
index superior to 1 corresponds to the amplification of a given VB subset. This calculation was also used for the CD8 + T cell subset (M). (am) Medium; 
(ll) ETA small calls; (~) ETA blast calls. 
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Vj88- and V~12-specific Stimulation of Peripheral Human T 
Cells by ETA.  Streptococcal ETA is a potent superantigen 
(22, 24). In vitro activation of PBMC from control donors 
by ETA leads to blastogenesis easily identified by FACS  ~ anal- 
ysis. Two populations (K1 and R2) can be distinguished con- 
sidering both the size (FSC) and the granulosity (SSC) of 
activated ceils (Fig.  1 B): blastic cells (gate R2) appear larger 
and more granular than nonblastic cells (gate R1), the latter 
exhibiting size and granulosity ofex vivo, nonstimulated lym- 
phocytes (Fig.  1A). Analysis of the VB usage by CD4 + and 
CD8 + T calls responding to ETA was performed with Abs 
against members of the VflS, V~8, and V/312 families. Fig. 
1, F-K show the percentages of CD4 + T cells stained with 
each anti-VB among the two distinct populations, small cells 
in K1 and blastic cells in R2. It appeared that ETA stimu- 
lates preferentially VB8 + T  cells as well as VB12 + T  ceils 
(Fig.  1,J and K). Indeed T cells bearing VB8 or VB12 were 
almost all found in the R2 population (compare Fig.  1, J 
to G and K to H). By contrast, T cells expressing VB5 were 
especially found in the nonblastic R1 population (Fig.  1 F). 
These same results were found for the CD8 § T  cell popu- 
lation (Fig. 1 M), confirming previous studies indicating that, 
in vitro, both CD4 + and CD8 + T  ceils are stimulated by 
ETA (22,  25). 
To adequately compare among different donors, T cell sub- 
populations bearing a given V~ after ETA stimulation, results 
were calculated as the percentage of T  cell blasts bearing a 
particular V~ after stimulation divided by the percentage of 
T ceils bearing that V~ before stimulation. This calculation, 
proposed initially by Kappler et al. (1) was designed to cor- 
rect for variations in V~ expression from one person to an- 
other. In addition, it allowed one to visualize an amplification 
of a given V~ T cell subset after stimulation, namely when 
the index was superior to 1. This calculation was always used 
throughout this study. 
The ratio of T ceils bearing a particular V/~ before (Fig. 
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Figure 2.  V/~-specitic  stimulation of CD4 + and CD8 + T cells from HIV-infected  donors. PBMC from HIV-infected  donors were stimuhted by 
ETA as described  in Fig. 1. Anal)sis of V/3 usage of CD4+ and CD8 + T cells in response to ETA and index calenlation  were performed  as described 
in Fig. 1. Results of a representative  experiment are shown. 
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medium alone) was close to 1 (Fig. 1, L and M). In contrast, 
it was dear that T cells bearing Vfl8 and Vf112 were enriched 
in blasts produced by activation with ETA (ratio 4, 4 and 
4,  1,  respectively  for CD4 + T  cells and 2,3  and 2,5  for 
CD8 + T  cells), whereas T  cells bearing Vfl5 were specifi- 
cally excluded from the ETA blasts  (ratio '~0.22).  Indeed 
Vfl5 + T  cells remained in the R1  nonblastic population. 
The enhanced ratio observed for this latter population does 
not correspond to a specific proliferation, but rather is a con- 
sequence of an apparent enrichment of the R1 population 
with Vfl5 + cells due to the disappearance from this popu- 
lation of the other subsets  (Vfl8 + and Vf112+) (Fig.  1, L 
and M). 
Analysis of the V~ Usage by CD4 + and CD8 + T Cells  from 
HIV-infected Patients in Response to ETA Stimulation.  An ex- 
tensive study of the Vfl usage of patients' T cells responding 
to ETA (summarized in Table 1) was performed in HIV- 
infected patients, most of which were asymptomatic at the 
beginning of this study. Experiments performed as described 
in Fig. 1 and index of Vfl stimulation calculated as mentioned 
above revealed that HIV-infected patients could be divided 
into two groups. The first, named "responder;' is represented 
by the patient FY in Fig. 2. The Vfl + T ceU subsets of these 
patients behaved as did those of the controls (Fig.  1) to a 
stimulation by ETA with a specific activation of the Vfl8 + 
and VB12 + subsets  among CD4 + (Fig.  2 A) and CD8 + 
(Fig. 2 B) T ceUs. The second, named "anergic" represented 
Table  1.  V~ usage by CD4 + T  Cells  from HIV-infected Donors in Response to ETA Stimulation* 
HIV + Vfl8 responders  HIV + Vfl8 anergic 
Donors  Vfl5.1,2,3  Vfl8  Vf112  Patients  Vfl5.1,2,3  Vfl8  Vf112  Patients  Vfl5.1,2,3  Vfl8  Vf112 
HIV-  controls 
C1  0.44  2.80  3.40  AT  0.05  2.41  4.86  AI  0.58  1.10  8.00 
C2  0.44  3.55  4.63  CE  0.27  2.93  7.17  BT  0.66  0.96  3.16 
C3  0.42  4.51  5.62  CT  0.10  3.58  4.63  BU  0.20  1.11  5.85 
C4  0.30  3.30  5.48  DO  0.02  2.57  4.49  CIL  0.06  0.26  9.60 
BR*  0.05  2.50  3.60  DS  0.25  3.78  8.70  CSS  0.30  0.66  2.20 
CY  0.40  3.53  5.13  DY  0.29  2.67  5.50  DA  0.20  0.80  10.93 
C5  0.13  4.38  4.10  EA  0.37  4.26  6.61  DD  0.15  1.52  4.63 
C6  0.16  3.81  6.97  GO  0.18  4.50  2.24  DI  0.46  1.03  8.14 
MA  0.19  4.05  4.34  GK  0.37  4.02  12.54  DR  0.32  0.42  5.26 
C7  0.24  2.55  3.85  HY  0.16  2.40  4.90  DT  0.26  0.79  3.26 
C8  0.27  3.38  4.32  MA  0.15  4.29  12.24  GE  0.09  1.29  2.92 
C9  0.10  2.76  2.61  MT  0.06  4.07  4.23  GG  0.25  0.31  3.45 
GN  0.38  2.60  3.22  PT  0.09  5.09  5.10  GT  0.35  1.56  8.62 
C10  0.15  2.37  5.11  PY  0.12  5.60  7.16  HE  0.06  0.83  11.42 
Cll  0.13  4.81  4.40  RE  0.30  2.40  4.58  HT  0.60  0.64  4.30 
ILL  0.41  6.06  6.81  HU  0.90  0.59  5.88 
RK  0.49  3.56  10.38  HZ  0.16  0.94  8.70 
TD  0.07  2.96  6.37  LE  0.38  1.05  3.54 
ZI  0.11  3.10  6.09  LI  0.56  1.52  5.97 
ME  0.17  1.26  7.72 
MN  0.46  0.98  7.21 
MY  0.10  1.20  9.79 
SN  0.17  1.05  4.70 
VT  0.36  0.33  6.44 
Mean  0.25  3.39  4.45  0.20  3.70  6.56  0.33  0.93  6.32 
( _+ SD)  (0.14)  (0.79)  (1.10)  (0.14)  (1.10)  (2.72)  (0.22)  (0.38)  (2.68) 
* Results are expressed as stimulation index corresponding to the percentage of CD4 § T cell blasts bearing a given Vfl after 4-d stimulation by 
ETA divided by the percentage of CD4 + T cells hearing that Vfl before stimulation, 
$ Infectious mononucleosis (MNI). 
$ Patient in CDC stage I. 
417  Da~g~o et ~. by the patient ME in Fig. 2, showed a Vfl8-specific lack of 
response to ETA stimulation:  the majority of Vfl8 + T cells 
were found in the small cell population (population R1). In- 
deed, after ETA stimulation,  the indexes of Vfl8 + T  cell in 
the blasts were around or below 1 in contrast  to those of 
Vf112 + T  cells which could reach 6-8 in the blasts of the 
same patient  (Fig.  2 and Table  1). The fact that  the Vfl8 + 
T cells did not disappear after ETA stimulation but remained 
in the small cell population (R1) indicated the existence of 
an anergic state in this subset rather than a specific deletion. 
Fig. 2 shows that this Vfl-specific anergy was found in both 
CD4 + and CD8 + T  cells. 
Table 1 summarizes the results from a series of experiments 
performed with lymphocytes from 43 HIV-infected patients 
and 15 seronegative donors. Interestingly, a large fraction of 
HIV-infected patients  showed a Vfl8-specific anergy in re- 
sponse to ETA since it concerned 56 % of the patients studied 
(24 over 43). This phenomenon was never observed in lym- 
phocytes from seronegative controls, including a patient in- 
fected by EBV infectious mononucleosis  (MNI) (Table  1). 
This anergy was not associated with a general unresponsive- 
ness to ETA,  since all  the patients  from the nonresponcler 
group showed a normal expansion of the Vf112 T cell subset 
in response to ETA, and the corresponding  mean index in 
T cell blasts was comparable to that of the responder group. 
By contrast, the absence of amplification of the Vfl8 + T cell 
subset in ETA-stimulated cultures from anergic patients was 
underlined by a mean index below 1 in T cell blasts as com- 
pared to 3.5 for the two other groups, responders and con- 
trols  (Table  1). 
Longitudinal study of 14 patients for over 1 yr indicated 
that anergy represented a constant and long-lasting phenom- 
enon. Comparison of the clinical status of responder vs. anergic 
patients indicate no correlation with the stage of the disease 
and previous viral or bacterial infections.  In addition it should 
be noted that  the unresponsiveness of the Vfl8 subset may 
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Figure  3.  Vfl8-spocific anergy of CD4 + T  cells in response to SEE. 
PBMC from a control donor or from HIV-infected patients belonging 
either to the responder or to the anergic group were stimulated for 4 d 
with ETA (1/~g/ml) or 11 d with SEE (1 tzg/ml), rIl.,2  (20 U/ml) was 
added at day 3 in SEE-stimulated cultures.  Analysis of Vfl usage of CD4 § 
T cells in response to these superantigens and index calculation were per- 
formed as described  in Fig,  1. Results of a representative experiment are 
shown. 
418  Vfl8-speciilc  T  Cell Anergy in HIV-infected  Individuals be a very early phenomenon since it was found in a patient 
at CDC stage I of the disease (see Table 1). Thus it appeared 
that the only known common factor between patients in all 
groups was HIV infection. 
Vfl8-specific Unresponsiveness Is Not Restricted to an ETA Stim- 
ulation but Represents an Intrinsic Functional Defect.  Since un- 
responsiveness of the V~8 T cell subset could be the conse- 
quence of a specific defect in the interaction  between this subset 
and streptococcal ETA, we analyzed the response to another 
bacterial superantigen, SEE. In addition to stimulating T cell 
subsets expressing the V~5.1, V~36, and VB18 dements, SEE 
activates also the VB8 + T  cell subset (1, 26).  Comparison 
of the in vitro SEE and ETA stimulation  on the expansion 
of the VB8 CD4 + T cell subset from the two groups of pa- 
tients is shown in Fig.  3.  No amplification  of the V~8 T 
cdl subset was observed after SEE  stimulation  of lympho- 
cytes from a nonresponder patient, whereas in the same cul- 
ture, the expected amplification of the VB5.1 subset occurred. 
The  same results were observed in  the CD8 + T  cell sub- 
population  (data  not  shown),  although  the  SEE-activated 
population  which was predominantly  CD4 + blast cells  in 
response  to  SEE,  is  composed  of 90%  CD4 +  and  10% 
CD8 + T cells as compared to 50% CD4 + and 50% CD8 + 
T cells in response to ETA. A comparison of SEE and ETA 
stimulations  on lymphocytes from eight patients from the 
anergic group confirmed that  the anergy was never found 
in the VBS.1 and V/312  subsets (data not  shown). 
To confirm that the VB-specific anergy was not only as- 
sociated to a superantigenic activation but rather represented 
an intrinsic functional defect, stimulations were performed 
with anti-V~ mAbs and compared to those induced by ETA 
and SEE. Table 2 shows a representative experiment in which 
T ceils from three responder patients were significantly stimu- 
lated by coated anti-VB8 mAbs, as well as by anti-V~5.1 and 
anti-V1312 mAbs. On the contrary, T cells from three anergic 
patients were not sensitive to anti-V~8 stimulation whereas 
they were normally stimulated by anti-V~12 and anti-VBS.1 
mAbs.  As expected,  the VB8-specific anergy was also ob- 
served in response to ETA and SEE, each superantigen repre- 
senting a control of the mAb stimulation since SEE activated 
V/35.1 and VB8 subsets whereas ETA activated VB8 and V/312 
subsets. Thus,  the anergic state observed in response to su- 
perantigens was specific and intrinsic to the V~8 T cell subset. 
Anergic  Vj88  T  Cells Do Not Express IL-2Rs and Are Un- 
responsive to Exogenous Cytokines.  In vivo administration of 
the superantigen staphylococcal enterotoxin B (SEB) (19-21) 
or immunization  of Mls-1 b mice by Mls-1 a spleen cells (18) 
have been reported to induce in mice a peripheral T cell toler- 
ance characterized by the anergy of T cell subsets expressing 
specific VI3 determinants.  In these models, the anergic subset 
expressed the IL-2gs partially (19) or normally (18), but failed 
to respond to exogenous IL-2 (18, 19, 27). Since our results 
suggest the induction,  in the course of HIV infection, of a 
VB-specific peripheral  tolerance,  we analyzed whether  the 
IL-2/IL-2Rs pathway was affected in the V~8 anergic subset. 
IL-2gs (CD25) expression was studied on the V~5, Vr 
and V~12 subsets after 4 d of stimulation with ETA. To com- 
pare the V~8 anergic subset to the others, CD25 expression 
was analyzed on the R1 (small cells) population.  Results in 
Fig.  4  show that  ETA stimulation  induced  the expression 
Table  2.  V~8-specific Anergy Is Maintained after Activation by Anti-VB8 mAbs 
V~8 responder  patients 
V~ stimulation  of 
PBMC with* 
VB8 anergic patients 
V~ stimulation  of 
PBMC with* 
V~ expression  ETA  mAbs  V~ expression  ETA  SEE  mAbs 
Patients  studied  (index)*  (SI)S  Patients  studied  (index)*  (index)*  (SI)S 
CT  VB5.1  0.13  7.87  ME  V~5.1  0.17  5.03  3.54 
V~/8  3.58  11.33  V~8  0.90  1.24  1.19 
Vt812  5.83  8.80  V~12  12.9  0.98  6.23 
GO  V~8  3.86  2.40  AI  V~8  0.49  ND  0.32 
V~12  2.36  2.20  V~12  8.01  ND  2.55 
CE  V~8  3.25  2.47  HT  V~8  0.18  ND  0.99 
V~12  7.42  2.41  VB12  6.26  ND  2.69 
* Cells were stimulated for 4 d with ETA (1/~g/ml), for 11 d with SEE (1/~g/ml) or for 6 d with anti-V/~ mAbs. rlL-2 was added (20 U/ml) 
at day 3 in the last two cultures. 
* Index represents the percentage of CD3+ T calls bearing a given V~ after ETA or SEE stimulation divided by the percentage of CD3 + T cells 
bearing that V~ before simulation. 
$ SI corresponds to cpm obtained for cultures in microwells  coated with corresponding VB mAbs, divided by cpm obtained in medium alone. Values 
correspond to mean index of triplicate wells. 
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Figure 5.  Anergic V38 T cells 
are unresponsive to exogenous IL-2 
and IL-4. PBMC from anergic pa- 
tient HZ (/eft) or responder patient 
BD (right)  were stimulated for 6 d 
by ETA (1 /~g/ml) in the absence 
or in the presence  of  dD2 (20 U/ml) 
or rIL-4 (4 ng/ml). Analysis of Vfl 
usage of CD4 + and CD8 + T cells 
in response to ETA stimulation  and 
index  calculation  were  performed  as 
described in Fig. 1. Results of this 
experiment are representative  of a 
number  of fimilar  experiments  per- 
formed  on anergic  and responder  pa- 
tients. 
of IL-2tLs on a high percentage of small T cells expressing 
V312 element in the three groups of donors, indicating that 
expression of IL-2Rs precedes blastogenesis. Although a dis- 
persion of CD25 expression among donors was noticed (prob- 
ably due to an asynchronous activation), no signiiicative differ- 
ence in the V/~12 subset was found between controls (C), 
responder (R), and nonxesponder (NR) groups. 
By contrast, CD25 expression by the anergic V38 subset 
was very low for all the nontesponder patients and a significant 
difference (p <0.001) was found between the anergic group 
and the two other groups (Fig. 4). h  is noteworthy that the 
anergic V/$8 subset behaves like the V35 subset from the three 
groups, this latter subset being insensitive to ETA activation 
(Fig.  4). 
Addition of rIL-2 at the initiation of ETA stimulation could 
not reverse the anergic state of the V38 subset (Fig. 5). Similar 
results were obtained with a crude preparation of cytokines 
(TCGF) (data not shown). The influence of IL-4 was also 
studied since a recent study indicated that infection of SEB- 
tolerant mice with NiFpostrongylus brasiliensis (known to in- 
duce a high IL-4 secretion in normal mice) circumvented the 
anergy of the CD4 +V38 + T  cells (28).  Fig.  5 shows that 
the V3-specific anergy observed in the course of HIV infec- 
tion could not be reversed by IL-4. 
Discussion 
Peripheral tolerance, due either to T cell deletion or anergy, 
plays a major role in the suppression of autoimmunity (29, 
30). Whereas deletion has been convindngly demonstrated 
for immature T  cells recognizing sdf-determinants during 
thymic development (29, 31-33), functional anergy has been 
recently demonstrated for peripheral T cells exposed to su- 
perantigens in vivo.  Thus, murine T  cells bearing V/36  + 
TCR, specific for determinants encoded by the Mls-l' locus, 
are rendered unresponsive to MIs-P in vitro after prior ex- 
posure to Mls-l~-bearing cells in vivo (18, 27, 34). Similarly, 
V38 + T cells no longer respond in vitro to SEB when taken 
from SEB-primed mice (19-21, 35). In this report, we show 
the existence, in an important fraction of HIV-infected indi- 
viduals,  of a  V3-specific clonal  anergy that  affects both 
CD4 + and CD8 + T cells. The V38-specific unresponsive- 
ness we observed in response to streptococcal  superantigen 
ETA was not the consequence of a defective presentation of 
ETA since in the same cultures, the V312 + population was 
always normally stimulated by this antigen. In addition, the 
V~8 anergy was also observed in response to another bac- 
terial superantigen, SEE. The failure of anti-V38 mAbs to 
stimulate this subset indicates  that this V3-specific anergy 
represents an intrinsic functional defect rather than a specific 
lack of response to certain bacterial  superantigens. 
Inactivation or ddetion of superantigen-reactive T cells by 
acute confrontation with superantigen is preceded by specific 
activation of these cells (35-37). Several recent reports have 
discussed attempts to indirectly reveal the presence of an HW- 
associated superantigen by looking for consistent amplifica- 
tions and/or deletions in the peripheral TCR V3 repertoire 
of HIV-infected individuals. A more restricted V/3 repertoire 
(V/~14 through V/320 appeared to be deleted) was found in 
HIVqnfected patients  with  advanced  disease  (15) and  a 
significant increase of peripheral CD4 + T cells of the V35.3 
subfamily was reported in asymptomatic subjects (16). Per- 
turbations in the V3 repertoire were also found in several 
pairs of monozygotic twins discordant for HIV with iden- 
tical MHC (17), allowing meaningful comparisons of their 
V3 repertoire, since one of the major factors that influence 
Figure 4.  Anergic V38 T  cells do not express ID2R after ETA-activation. (A-F) PBMC from an HIV-infected V38-responder  (patient  PT) and 
V38 anergic (patient ZI) were stimulated for 4 d by ETA (1/~8/ml). Expression of CD25 was determined in the R1 population (small cells) by dual 
staining of T cell subsets expressing V35.1,2,3  (.4 and D), V/~8 (B and E) and V/~12 (C and F) dements. (G) This same analysis was performed after 
ETA activation of T cells from seronegative controls C (n  -  6), V38 responders R  (n  s  9) or anergic NR (n  *  8) HIV-infected donors. Resuks 
are expressed as the pezcentage of CD25 + T cells in the ILl population among a given VO T  cell subset. Each symbol corresponds to a single in- 
dividual. A significative difference in the expression of CD25 was only observed for the V38 + subset from the anergic patients as compared to that 
of control or responder donors  (p g0.001 by Mann-Whitney U  test). 
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class II haplotype of the individual (38). Our study provides 
evidence that a dominant superantigen may be involved early 
in the course of HIV infection. 
Since in mice in vivo administration of a superantigen in- 
duces, in addition to clonal anergy, varying degrees of clonal 
deletion (2,  18-21, 36, 39, 40), we compared ex vivo VB8 
expression by CD4+  and CD8+  T cells from anergic sub- 
jects to that of responder and control subjects, but we could 
not detect any deletion or underrepresentation of this subset 
in anergic  patients (mean values:  4.95%  V/~8+CD4 +  +- 
1.90;  4.03%  VB8+CD8 +  +  1.88  in  nonresponders vs. 
4.24%  V/58+CD4 +  +  1.26  and 4.04%  V~8+CD8 +  + 
2.17 in responders). Clonal deletion, however, is not an oblig- 
atory consequence of anergy induction and anergized cells 
may persist for extended periods of time (18, 27, 36). In ad- 
dition, the outbred nature of human populations is an im- 
portant obstacle to an accurate comparison of V/5 repertoires. 
In vitro models of T cell anergy suggest that a major de- 
fect in these cells is their inability to produce IL-2, whereas 
anergized cells are fully responsive to exogenous IL-2 (41). 
Models of in vivo-induced anergy (18, 19, 21, 27, 37) and 
the present data, suggest a more profound defect. Upon in 
vitro restimulation with ETA,  anergic VB8 + T  cells from 
HIV-infected individuals do not express IL-2Rs at all. These 
cells are also unresponsive to exogenous IL-2 or IL-4. It sug- 
gests that unresponsiveness  of the anergized V~8 § T  cells 
appearing in the course of HIV infection is not a reversible 
process, at least by the use of these cytokines. Indeed, a 1-yr- 
longitudinal study of HIV-infected subjects belonging to re- 
sponder or anergic group indicates that the V/3 anergic status 
is not a transient phenomenon, which may reflect a chronic 
exposure to the superantigen. 
Several observations are in favor of a direct involvement 
of HIV in the V~-specific anergy observed in asymptomatic 
HIV-infected individuals: (a) anergy can be observed very 
early in the course of HIV infection e.g., in T  cells from a 
primo-infected patient (CDC stage I); (b) comparison of the 
clinical status of responder vs. anergic patients showed no 
correlation with previous viral or bacterial  infections, sug- 
gesting that anergy may not be induced by opportunistic 
pathogens; (c) inactivated HIV is able to induce, in vitro, 
a strong proliferation of normal peripheral lymphocytes and, 
concomitantly, the sdective expansion of the V~8 + T  cdl 
subset is reproducibly detected (Poccia, F., and M. L. Gou- 
geon, manuscript in preparation). 
Except for the acute pathogenic variant of simian im- 
munodeficiency  virus PBj14 (42), no report has shown until 
now the ability of HIV to activate normal peripheral T cells. 
Since a selective expansion of superantigenic-reactive  T ceils 
is known to precede anergy,  one can speculate that in vivo 
infection of CD4 + ceils will release viral  protein(s) con- 
taining Vfl-specific dements and presentation of this super- 
antigen to T cells, in association with MHC class II mole- 
cules, will induce activation followed by anergy of subsets 
bearing the cognate Vfl determinants. It is interesting to note 
that the putative viral superantigen involved in this process 
has no sdective tropism for CD4 + T cells, since both CD4 + 
and CD8 + T cells are found to be anergic in patients. A re- 
cent report (43) described the dependence of HIV-1 replica- 
tion on a  superantigen and it  concerned particularly the 
Vf112 § CD4 § cell subset which replicated more e~ciently 
HIV in vitro and which was found enriched for gp120- 
expressing cells in vivo. Our study is probably concerned with 
another superantigen, since the Vfl specificity involved is 
different and its mode of action also may be different since 
we never found a Vfll2 anergy in patients' peripheral T cells. 
The fact that Vfl8 anergy is not observed in all HIV-infected 
individuals but in 56%  of them may be related to at least 
two factors: the dependence of the HLA-DR phenotype of 
presenting cells for the ef~cacy of the putative superantigen 
(38, 44, 45), and the possible requirement, for the acquisi- 
tion of super'antigenic  activity, of mutations in the viral protein. 
The involvement of superantigeus has been recently sug- 
gested in autoimmune diseases such as rheumatoid arthritis 
(46) or multiple sclerosis (5, 47) and the expansion oft cells 
expressing TCR Vfl2 and Vfl8 has been reported in patients 
in the acute phase of Kaw saki disease (48). The influence 
of a superantigen in these pathologies was suggested by en- 
hancement of T  cell subsets expressing given VB dements 
or by skewed TCR repertoire.  Our study reports for the first 
time in humans a specific  V~ anergy associated  with a retroviral 
infection. It is unclear what role a viral superantigen may 
play in rendering target T ceils anergic or susceptible to dele- 
tion by apoptosis (49-52).  Activation of a significant  frac- 
tion of CD4 cells by a superantigen would greatly increase 
the number of cells susceptible to virus infection and replica- 
tion (43), contributing to viral dissemination and progres- 
sive immune failure.  Encoding for superantigenic protein 
would also help the virus to escape from the immune system 
by inducing anergy in CD8 + cytotoxic T  ceUs that kill 
infected cells. Thus an as yet unidentified HIV-l-encoded 
superantigen could contribute, in addition to other cytopatho- 
genic mechanisms, to the profound immunodeficiency ob- 
served in HIV infection. 
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